Seres Therapeutics (MCRB) Company presentation summary

Strategic focus and pipeline advancement

• Advancing live biotherapeutic programs targeting inflammatory and immune diseases, with a focus on SER-155 and SER-603.

• SER-155 is Phase 2 ready for allo-HSCT patients, with expansion potential to autologous HSCT and broader blood cancer populations.

• SER-603 is in preclinical development for IBD, aiming to improve response and durability to current therapies.

• SER-147 targets infection prevention in cirrhosis and is in preclinical IND-enabling studies.

• Ongoing efforts to secure funding and partnerships to support pipeline progression.

Clinical and commercial highlights

• SER-155 demonstrated 77% relative risk reduction in bloodstream infections in Phase 1b allo-HSCT study, with a placebo-like safety profile.

• SER-155 reduces systemic antibiotic use and febrile neutropenia, with no serious adverse events attributed to the drug.

• VOWST, an approved oral microbiome therapeutic, was sold to Nestlé, providing milestone payments and validating commercial potential.

• SER-603 shows preclinical efficacy in reducing inflammation and improving response to anti-TNFα therapy in IBD models.

• SER-147 demonstrates reduction in E. coli and protection of epithelial barrier in preclinical models.

Platform and operational capabilities

• Proprietary AI-enabled MbTx platform enables discovery, optimization, and clinical translation of live biotherapeutics.

• Proven regulatory expertise with FDA approvals and established manufacturing processes for oral formulations.

• Field-leading capabilities in microbiome biomarker identification, clinical trial execution, and patient-centric drug development.

• Manufacturing platform supports cost-effective, scalable production and global clinical trial supply.

• Biomarker-driven approach enables precision medicine and identification of patient subpopulations likely to benefit.